UCB successfully completes its fixed rate bonds - Early termination
of the offer period - Total amou
(Thomson Reuters ONE) - THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INOR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHERJURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BYAPPLICABLE LAWThe current news release constitutes regulated information as definedin the Belgian Royal Decree of November 14, 2007, regarding theobligations of issuers of financial instruments that have beenadmitted to trading on a regulated marketBrussels, Belgium, October 27, 2009, 17.30 (CET) - UCB SA/NV ("UCB"or the "Company") announces today that it has successfully completedthe placement of its 5.75% fixed rate bonds through a public offeringin Belgium and Luxembourg. The offer period has been early terminatedon October 27, 2009 at 5:30 pm. The aggregate nominal amount of thebonds has been set at EUR 750 million.The net proceeds from the issue of the bonds will be used by UCB forgeneral corporate purposes and form part of UCB's fundingdiversification policy.The payment date will be November 27, 2009.BNP Paribas Fortis, ING and KBC Bank act together as lead managersfor this transaction.The bonds will be listed on the Luxembourg Stock Exchange.Detlef Thielgen, CFO of UCB, said: "We are very pleased with thestrong support UCB receives in Belgium and Luxembourg and togetherwith the recent convertible bond issuance, this operation confirmsour ability to access various international Capital Markets."For further informationRichard Simpson, Investor Relations, UCBT+32.2.559.9494, richard.simpson(at)ucb.comMichael Tuck-Sherman, Investor Relations, UCBT +32.2.559.9712, michael.tuck-sherman(at)ucb.comNancy Nackaerts, External Communications, UCBT +32.473.864.414, nancy.nackaerts(at)ucb.comAbout UCBUCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical companydedicated to the research, development and commercialization ofinnovative medicines with a focus on the fields of central nervoussystem and immunology disorders. Employing approximately 10 000people in over 40 countries, UCB generated revenue of EUR 3.6 billionin 2008. UCB is listed on Euronext Brussels (symbol: UCB).Forward looking statementThis press release contains forward-looking statements based oncurrent plans, estimates and beliefs of management. Such statementsare subject to risks and uncertainties that may cause actual resultsto be materially different from those that may be implied by suchforward-looking statements contained in this press release. Importantfactors that could result in such differences include: changes ingeneral economic, business and competitive conditions, effects offuture judicial decisions, changes in regulation, exchange ratefluctuations and hiring and retention of its employees.DisclaimerTHIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INOR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHERJURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BYAPPLICABLE LAWTHE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER AND SALE OF THESECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONSMAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENTSHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.ANY OFFERING AND ANY RELATED FORMAL DOCUMENTATION WILL BE SUBJECT TOCONDITIONS AND TERMINATION EVENTS, INCLUDING THOSE WHICH ARECUSTOMARY FOR SUCH OFFERINGS. ANY SUCH OFFERING WILL NOT COMPLETEUNLESS SUCH CONDITIONS ARE FULFILLED AND ANY SUCH TERMINATION EVENTSHAVE NOT TAKEN PLACE OR THE FAILURE TO FULFILL SUCH A CONDITION ORTHE OCCURRENCE OF A TERMINATION EVENT HAS BEEN WAIVED, IF APPLICABLETHIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES IN THE UNITED STATESOR ANY OTHER JURISDICTION. THE BONDS (AND THE COMPANY'S SHARES) MAYNOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR ANEXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT OF 1933, ASAMENDED (THE "SECURITIES ACT"). UCB DOES NOT INTEND TO REGISTER ANYPORTION OF THE PLANNED OFFER IN THE UNITED STATES OR TO CONDUCT ANOFFERING OF SECURITIES IN THE UNITED STATES. THE OFFERING IS BEINGCONDUCTED OUTSIDE THE UNITED STATES IN ACCORDANCE WITH REGULATION SUNDER THE SECURITIES ACT.THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS WITHIN THEMEANING OF DIRECTIVE 2003/71/EC OF THE EUROPEAN PARLIAMENT AND THECOUNCIL OF NOVEMBER 4, 2003 (AS IMPLEMENTED IN EACH MEMBER STATE OFTHE EUROPEAN ECONOMIC AREA, THE "PROSPECTUS DIRECTIVE").THE DEFINITIVE TERMS OF THE TRANSACTIONS DESCRIBED HEREIN WILL BEDESCRIBED IN THE PROSPECTUS TO BE PREPARED IN RELATION TO THESECURITIES (THE "PROSPECTUS"). INVESTORS SHOULD NOT SUBSCRIBE FOR ANYSECURITIES REFERRED TO HEREIN EXCEPT ON THE BASIS OF INFORMATIONCONTAINED IN THE FINAL FORM OF THE PROSPECTUS.THIS ANNOUNCEMENT IS DIRECTED ONLY AT THE FOLLOWING PERSONS IN THEUNITED KINGDOM: (I) PERSONS WHO HAVE PROFESSIONAL EXPERIENCE INMATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THEFINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER2005 (THE "ORDER"), (II) PERSONS FALLING WITHIN ARTICLE 49 OF THEORDER AND (III) PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BECOMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS"QUALIFIED PERSONS"). IN THE UNITED KINGDOM, THIS ANNOUNCEMENT ISONLY DIRECTED AT QUALIFIED PERSONS AND ANY INVESTMENT OR INVESTMENTACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS ONLY AVAILABLE TOQUALIFIED PERSONS OR WILL BE ENGAGED IN ONLY BY QUALIFIED PERSONS.SOLICITATIONS IN THE UNITED KINGDOM RESULTING FROM THIS ANNOUNCEMENTWILL BE RESPONDED TO IF THE PERSON CONCERNED IS A QUALIFIED PERSON.OTHER PERSONS SHOULD NOT RELY OR ACT UPON THIS ANNOUNCEMENT OR ANY OFITS CONTENTS.ANY PURCHASE OF OR APPLICATION FOR BONDS OF THE COMPANY PURSUANT TOTHE OFFERING SHOULD ONLY BE MADE ON THE BASIS OF THE INFORMATIONCONTAINED IN THE PROSPECTUS TO BE ISSUED BY THE ISSUER IN DUE COURSEIN CONNECTION WITH THE OFFERING.For the pdf-version of this press release, please click on the linkbelow:http://hugin.info/133973/R/1350405/325875.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 27.10.2009 - 17:31 Uhr
Sprache: Deutsch
News-ID 7474
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 370 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"UCB successfully completes its fixed rate bonds - Early termination
of the offer period - Total amou"
steht unter der journalistisch-redaktionellen Verantwortung von
UCB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
